Sven Schnichels
Dr. rer. nat.
Group Leader "Neuroprotection & Drug Delivery"
Business address
Institute for Ophthalmic Research
University of Tübingen
Elfriede-Aulhorn-Strasse 7
D-72076 Tübingen,
Germany
Phone: +49 (0)7071 29-87888
E-mail: sven.schnichels@med.uni-tuebingen.de
Academic Education
| 2006 - 2010 | Dr. rer. nat. (PhD), Ophthalmology / Neuroscience, Eberhard Karls University, Tübingen, Germany |
| 2000 - 2005 | Diploma, Biology, University of Hohenheim, Stuttgart, Germany |
Professional Experience
| Since 2016 | Group Leader, Ophthalmology / drug-delivery, University Eye Hospital Tübingen |
| Since 2013 | Laboratory Head, Ophthalmology / drug-delivery, University Eye Hospital Tübingen |
| 2011 - 2013 | Laboratory Head Preclinical Research, Ophthalmology / drug-delivery, University Eye Hospital Tübingen |
| 2009 - 2011 | Post-Doc, Ophthalmology / Neuroscience, University Eye Hospital Tübingen |
| 2006 - 2009 | PhD position, Ophthalmology / Neuroscience, University Eye Hospital Tübingen |
Professional Activities and Functions
Academic Awards
| since 2019 | European Leadership Development Programme (EuLDP), European Society of Ophthalmology (SOE) |
| 2021 | DOG-Glaucoma Research Award sponsored by Santen, Germany |
| 2021 | Dr. Gaide-AMD-Award, German Retina Society |
| 2019 | Research Award of the Boni-Tschönhens-Foundation |
| 2019 | Poster award: Makula Update 2019, Novartis, Germany |
| 2018 | DOG-Patent-Award of the Deutsche Ophthalmologische Gesellschaft sponsored by Heidelberg Engineering |
| 2018 | AECOS European Research Award 2018: American-European Congress of Ophthalmic Surgery |
| 2016 | Poster award: Research Colloquium of the Medical Faculty Tübingen 2016 |
| 2015 | Poster award: 113. Congress of the Deutsche Ophthalmologische Gesellschaft |
| 2015 | Science4Life (Business Plan Competition), Winner Idea + Concept Phase |
| 2015 | 2. Scientific Prize Verein Rheinisch-Westfälischer Augenärzte |
| 2014 | Poster award: 112. Congress of the Deutsche Ophthalmologische Gesellschaft |
| 2014 | 2. Place: Science2Start from BioRegio STERN Management |
| 2013 | 1. Place: EYEnovative Research Prize from Novartis |
| 2012 | 1. Place: NGI (Netherlands Genomics Initiative) Venture Challenge |
| 2011 | Poster award: 109. Congress of the Deutsche Ophthalmologische Gesellschaft |
| 2010 | Poster award: Tübingen Outer Retina Conference (TORC) |
| 2010 | Poster award: Young Researcher Vision Camp 2010 |
Memberships
| Since 2018 | International Society for Eye Research |
| Since 2012 | Deutsche Ophthalmologische Gesellschaft (DOG) |
| Since 2010 | Association for Research in Vision and Ophthalmology (ARVO) |
| Since 2010 | Neurowissenschaftliche Gesellschaft (NWG) |
| Since 2007 | Society for Neuroscience (SfN) |
Travel Grants
| 2011 – 2019 | 7x DAAD: ARVO Meetings in Baltimore, Denver, Orlando, Seattle, Fort Lauderdale, USA & Vancouver, Canada |
| 2012 | GlaxoSmithKline Foundation to the FENS Meeting 2012 in Barcelona, Spain |
| 2009 | Reinhold-und-Maria-Teufel-Stiftung to the Neuroscience Meeting 2009 in Chicago, USA |
Committees
| Since 2021 | Project group German Center for Health Research: Ophthalmology (DOG) |
| Since 2019 | Scientific Committee European Vison Camp |
| Since 2019 | Programme Committee, German Ophthalmic Society (DOG) |
Since 2019 | Junior Academy Medical Faculty, Tübingen, Germany |
| Since 2018 | Scientific Advisor: Robert Bosch GmbH, Germany |
| Since 2018 | Board of Directors, German Ophthalmic Society (DOG) |
| Since 2018 | Speaker YoungDOG (German Ophthalmic Society) |
Additional information
Ad-Hoc Reviewer (Selection)
Investigative Ophthalmology & Visual Science; Scientific Reports; Acta Ophthalmologica; Experimental Eye Research; Clinical and Experimental Ophthalmology; Organic & Biomolecular Chemistry; Journal of Neuroinflammation; Journal of Molecular Neuroscience; Nanotoxicology; Journal of Visualized Experiments; Vision Research; International Journal of Molecular Sciences; Journal of Pharmaceutical and Biomedical Analysis, Drug Design, Development and Therapy; Regulatory Toxicology and Pharmacology; Cell and Tissue Research; Cellular Physiology and Biochemistry; Pharmaceutics; Cells; BMC Ophthalmology; Journal of Ocular Pharmacology and Therapeutics; Der Ophthalmologe; Colloids and Surfaces B: Biointerfaces; International Journal of Nanomedicine; Biomedical Optics Express;
Foundations and Funding organisations:
Ernst und Berta Grimmke Stiftung; Deutsche Ophthalmologische Gesellschaft; fwo; Ghent University; Christian Doppler Forschungsgesellschaft, Österreichische Forschungsförderungsgesellschaft; Health Research Charities Ireland (HRCI)-Health Research Board (HRB),
Patents
A. Herrmann; J.W. de Vries; M.S. Spitzer; S.O. Schnichels, Means and Methods for Ocular Drug Delivery, PCT/NL2014/050634, EP3057572B1 and US10285939B2
Past and Current Funding
| 2021 - 2022 | Research grant: GO-Bio Initial, BMBF, Germany: REVeyeVE |
| 2019 - 2023 | Research grant from Novartis Pharma GmbH, Germany |
| 2020 - 2021 | Research grant: Helmut Ecker Stiftung, Germany |
| 2019 - 2020 | Intramural research grant of the ƒortüne-Program of the Tübingen medical faculty |
| 2019 | Industry grant from DORC & University Leiden, The Netherlands |
| 2018 - 2020 | Industry grant from Robert-Bosch GmbH, Germany |
| 2017 - 2019 | Research grant from the PRO RETINA-Stiftung, Germany |
| 2016 - 2019 | Research grant from the SET-Stiftung, Germany |
| 2016 - 2019 | Research grant: Ministry of Rural Affairs & Consumer Protection Baden-Württemberg, Germany |
| 2014 - 2017 | Research grant (EXIST-Forschungstransfer): German federal ministry for economic affairs & energy |
| 2014 - 2016 | Research grant from the SET-Stiftung, Germany |
| 2013 - 2016 | Research grant from the Bundesinstitut für Risikobewertung (BfR), Germany |
| 2013 - 2014 | Intramural research grant of the ƒortüne-Program of the Tübingen medical faculty |
| 2013 - 2016 | Coaching grant from the European Social Fund (ESF) |
| 2012 - 2014 | Industry grant from Clanotech, Sweden |
| 2011 - 2016 | Industry grants (3) from CROMA, Austria |
Selected Publications
- Schnichels S+, Hurst J, de Vries JW, Ullah S, Frößl K, Gruszka A, Löscher M, Bartz-Schmidt KU, Spitzer MS, Herrmann A. Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9445-9456. Epub 2021 Feb 2. IF: 9,229
- Schnichels S+, Paquet-Durand F, Löscher M, Tsai T, Hurst J, Joachim SC, Klettner A. Retina in a dish: Cell cultures, retinal explants and animal models for common diseases of the retina. Prog Retin Eye Res. 2020 Jul 25:100880. Online ahead of print. IF: 21,198; Review
- Schnichels S+, Hurst J, de Vries JW, Ullah S, Gruszka A, Kwak M, Löscher M, Dammeier S, Bartz-Schmidt KU, Spitzer MS, Herrmann A. Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment. Nanomedicine. 2020 Oct;29:102260. Epub 2020 Jul 3. IF: 6,458
- Hurst J, Mueller-Buehl AM, Hofmann L, Kuehn S, Herms F, Schnichels S +#, Joachim SC. iNOS-inhibitor Driven Neuroprotection in a Porcine Retina Organ Culture Model J Cell Mol Med. 2020 Apr;24(7):4312-4323. Epub 2020 Mar 4. IF: 5,310
- Wu Z, Troll J, Jeong HH, Wei Q, Stang M, Ziemssen F, Wang Z, Dong M, Schnichels S, Qiu T & Fischer P A swarm of slippery micropropellers penetrates the vitreous body of the eye. Sci Adv. 2018 Nov 2;4(11):eaat4388. IF: 12,804
- de Vries JW, Schnichels S*, Hurst J, Strudel L, Gruszka A, Kwak M, Bartz-Schmidt KU, Spitzer MS & Herrmann A DNA nanoparticles for ophthalmic drug delivery. Biomaterials. 2018 Mar;157:98-106. Epub 2017 Nov 29. IF: 10,279
- Schnichels S+, Dorfi T, Schultheiss M, Arango-Gonzalez B, Bartz-Schmidt KU, Januschowski K, Spitzer MS & Ziemssen F Ex-vivo-examination of ultrastructural changes in organotypic retina culture using near-infrared imaging and optical coherence tomography. Exp Eye Res. 2016 Jun;147:31-6. Epub 2016 Apr 21. IF: 3,332
- Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS & Aisenbrey S Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013 Jul;97(7):917-23. Epub 2013 May 17. IF: 2,809
- Gaub P, Joshi Y, Wuttke A, Naumann U, Schnichels S, Heiduschka P & Di Giovanni S The histone acetyltransferase p300 promotes intrinsic axonal regeneration. Brain. 2011 Jul;134(Pt 7):2134-48. IF: 9,457
- Heiduschka P, Schnichels S, Fuhrmann N, Hofmeister S, Schraermeyer U, Wissinger B & Alavi MV Retinal ganglion cells are primarily affected in an animal model of OPA1 associated autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1424-31 2009 Oct 15. IF: 3,466